Developing live Shigella vaccines using λ red recombineering

FEMS Immunology and Medical Microbiology

Volumn 47, Issue 3, 2006, Pages 462-469

  Ranallo, Ryan T ^a   Barnoy, Shoshana ^a   Thakkar, Sejal ^a   Urick, Tonia ^a   Venkatesan, Malabi M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Attenuation; Recombination; Shigella vaccine

Indexed keywords

CARRIER PROTEIN; GENOMIC DNA; PLASMID DNA; SHIGELLA VACCINE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIOPHAGE; DRUG EFFECT; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SHIGELLA;

BACTERIOPHAGE LAMBDA; GENE DELETION; GENETIC ENGINEERING; MUTAGENESIS, SITE-DIRECTED; RECOMBINATION, GENETIC; SHIGELLA; SHIGELLA VACCINES; VIRULENCE;

EID: 33745812873     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00118.x     Document Type: Article

References (30)

1. Bernardini ML, Mounier J, d'Hauteville H, Coquis-Rondon M & Sansonetti PJ (1989) Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci USA 86: 3867-3871.
2. Blomfield IC, Vaughn V, Rest RF & Eisenstein BI (1991) Allelic exchange in Escherichia coli using the Bacillus subtilis sacB gene and a temperature-sensitive pSC101 replicon. Mol Microbiol 5: 1447-1457.
3. Buchrieser C, Glaser P, Rusniok C, Nedjari H, D'Hauteville H, Kunst F, Sansonetti P & Parsot C (2000) The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Mol Microbiol 38: 760-771.
4. Cherepanov PP & Wackernagel W (1995) Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158: 9-14.
5. Coster TS, Hoge CW, VanDeVerg LL, et al. (1999) Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67: 3437-3443.
6. Court DL, Sawitzke JA & Thomason LC (2002) Genetic engineering using homologous recombination. Annu Rev Genet 36: 361-388.
7. Datsenko KA & Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97: 6640-6645.
8. Donnenberg MS & Kaper JB (1991) Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immun 59: 4310-4317.
9. Elsinghorst EA (1994) Measurement of invasion by gentamicin resistance. Methods Enzymol 236: 405-420.
10. Hamilton CM, Aldea M, Washburn BK, Babitzke P & Kushner SR (1989) New method for generating deletions and gene replacements in Escherichia coli. J Bacteriol 171: 4617-4622.
11. Hartman AB & Venkatesan MM (1998) Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect Immun 66: 4572-4576.
12. Jin Q, Yuan Z & Xu J (2002) Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res 30: 4432-4441.
13. Karnell A, Li A, Zhao CR, Karlsson K, Nguyen BM & Lindberg AA (1995) Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers. Vaccine 13: 88-99.
14. Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN & Hale TL (2004) Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72: 923-930.
15. Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC & Levine MM (1995) A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13: 1488-1494.
16. Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP & Levine MM (1996) Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 64: 4542-4548.
17. Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM & Levine MM (2000) Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun 68: 1034-1039.
18. Kotloff KL, Taylor DN, Sztein MB, et al. (2002) Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70: 2016-2021.
19. Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD & Levine MM (2004) Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 190: 1745-1754.
20. Mendizabal-Morris CA, Mata LJ, Gangarosa EJ & Guzman G (1971) Epidemic Shiga-bacillus dysentery in Central America. Derivation of the epidemic and its progression in Guatemala, 1968-69. Am J Trop Med Hyg 20: 927-933.
21. Metcalf WW, Jiang W, Daniels LL, Kim SK, Haldimann A & Wanner BL (1996) Conditionally replicative and conjugative plasmids carrying lacZ alpha for cloning, mutagenesis, and allele replacement in bacteria. Plasmid 35: 1-13.
22. Murphy KC & Campellone KG (2003) Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Mol Biol 4: 11.
23. Oaks EV, Wingfield ME & Formal SB (1985) Plaque formation by virulent Shigella flexneri. Infect Immun 48: 124-129.
24. Ohya K, Handa Y, Ogawa M, Suzuki M & Sasakawa C (2005) IpgB1 is a novel Shigella effector protein involved in bacterial invasion of host cells: its activity to promote membrane ruffling via RAC1 and CDC42 activation. J Biol Chem.
25. Philippe N, Alcaraz JP, Coursange E, Geiselmann J & Schneider D (2004) Improvement of pCVD442, a suicide plasmid for gene allele exchange in bacteria. Plasmid 51: 246-255.
26. Ranallo RT, Fonseka CP, Cassels F, Srinivasan J & Venkatesan MM (2005) Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73: 258-267.
27. Sansonetti PJ & Arondel J (1989) Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7: 443-450.
28. Venkatesan MM & Burland V (2004) Genomic-Scale Analysis of Virulence Plasmids: The Contribution of Plasmid-Borne Virulence Genes to Enterobacterial Pathogenesis, pp. 395-411. ASM Press, Washington, DC.
29. Venkatesan MM, Goldberg MB, Rose DJ, Grotbeck EJ, Burland V & Blattner FR (2001) Complete DNA sequence and analysis of the large virulence plasmid of Shigella flexneri. Infect Immun 69: 3271-3285.
30. Wei J, Goldberg MB, Burland V, et al. (2003) Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun 71: 2775-2786.